Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploring the Pharmacomicrobiomics of Depression
2024-518101-18-02Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of venlafaxine in major depressive disorder (MDD), sponsored by Radboud University Medical Center. Primary endpoints: Association between medication-induced changes in gut microbial profile and depression symptoms and Association between medication-induced changes in gut microbial profile and side effects. Started Jan 2025; status: completed.
02
Drugs
venlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2024-518101-18-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518101-18-02.